Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis by Bhattacharya, Debapriya et al.
Small Molecule-directed Immunotherapy against Recurrent
Infection byMycobacterium tuberculosis*□S
Received for publication, February 13, 2014, and in revised form, April 2, 2014 Published, JBC Papers in Press, April 7, 2014, DOI 10.1074/jbc.M114.558098
Debapriya Bhattacharya‡, Ved Prakash Dwivedi‡, MamoudouMaiga§, MariamaMaiga§, Luc Van Kaer¶,
William R. Bishai§, and Gobardhan Das‡1
Fromthe ‡LaboratoryMedicineandMedical Sciences, CollegeofHealth Sciences, University of KwazuluNatal, Durban4001, SouthAfrica,
the §Center for Tuberculosis Research,Department ofMedicine, The JohnsHopkinsUniversity, Baltimore,Maryland21231-1001, and the
¶Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
Background: M. tuberculosis evades host-immune-responses by polarizing T helper (Th)2 and regulatory T cell (Treg)
responses, which diminish protective Th1 responses.
Results:Mice that are unable to generate Th2 cells and Tregs are resistant toM. tuberculosis infection. Simultaneous inhibition
of these T cell subsets by therapeutic compounds dramatically reduced bacterial burden.
Conclusion: Inhibition of Th2 and Treg cells increases Th1 responses that protect againstM. tuberculosis infection.
Significance:As therapeutic agents employed here do not directly act on harbored pathogens, they should avoid generation of
drug-resistantM. tuberculosis variants.
Tuberculosis remains the biggest infectious threat to human-
ity with one-third of the population infected and 1.4 million
deaths and 8.7million new cases annually. Current tuberculosis
therapy is lengthy andconsists ofmultiple antimicrobials,which
causes poor compliance and high treatment dropout, resulting
in the development of drug-resistant variants of tuberculosis.
Therefore, alternate methods to treat tuberculosis are urgently
needed. Mycobacterium tuberculosis evades host immune
responses by inducing T helper (Th)2 and regulatory T (Treg)
cell responses, which diminish protective Th1 responses. Here,
we show that animals (Stat-6/CD4-TGFRIIDN mice) that
are unable to generate both Th2 cells and Tregs are highly resis-
tant to M. tuberculosis infection. Furthermore, simultaneous
inhibition of these two subsets of Th cells by therapeutic com-
pounds dramatically reduced bacterial burden in different
organs. This treatment was associated with the generation of
protective Th1 immune responses. As these therapeutic agents
are not directed to the harbored organisms, they should avoid
the risk of promoting the development of drug-resistant
M. tuberculosis variants.
Tuberculosis represents an enormous burden to global
health, with 8.7 million new cases and 1.4 million deaths
annually (1). Mycobacterium tuberculosis is primarily trans-
mitted through the respiratory route and causes active
tuberculosis in 5–10% of infected individuals. The host
response to the organism is a major determinant of the out-
come of infection, and cell-mediated immunity plays a cen-
tral role in host resistance to this deadly disease. Studies with
tuberculosis patients and in animal models have indicated
indispensable roles of both CD4 and CD8 T cells in host
resistance against M. tuberculosis infection (2). Conse-
quently, HIV-infected individuals are profoundly more sus-
ceptible to M. tuberculosis infection and reactivation of
latent infection (3, 4). Collectively, these studies have indi-
cated that CD4 T helper (Th)2 cells play a key role in con-
trolling human tuberculosis.
M. tuberculosis evades host immune responses by altering
the balance of Th cell responses. It is now clear that Th1 cells,
which produce IFN- and lymphotoxin, play a central role in
host resistance toM. tuberculosis infection. Therefore, humans
or animals with defective Th1 responses are highly susceptible
to M. tuberculosis infection and disease (5, 6). However, the
presence of Th1 cell responses is not sufficient to confer host-
resistance against M. tuberculosis infection (7, 8). Th2 cells,
which produce IL-4, IL-5, and IL-13, assist in disease progres-
sion by antagonizing Th1-type immune responses (6). Expres-
sion of IL-4 has been detected in human granulomas (9) and is
well correlated with the immunopathology predictive of tuber-
culosis (10, 11). Furthermore, strong Th2 responses have been
observed in Bacille Calmette Guérin-vaccinated patients who
failed to be protected againstM. tuberculosis infection (12, 13).
Similarly, IL-4-deficient mice display a partial resistance to
M. tuberculosis infection (14, 15). Therefore, these findings
suggest that Th2 cells contribute to susceptibility against
M. tuberculosis infection. Recent studies have further indicated
that M. tuberculosis induces antigen-specific, FoxP3-express-
ing regulatory T cells (Tregs) (16) in the draining lymph nodes
(17), which inhibit protective immune responses by hindering
IFN- production by T cells through production of TGF- and
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IL-10 (18–20), thereby promoting disease progression. There-
fore, to understand the relative importance of distinct Th cell
subsets required to confer resistance against tuberculosis, we
have generated animals with impairments in the generation of
eitherTh1 cells, Th2 cells, Tregs, or combinations of these cells.
These animals were infected with a low dose (110 bacilli/
mouse) of the virulent M. tuberculosis strain H37Rv through
the aerosol route. We demonstrated that animals that are
unable to generate Th2 cell responses and Tregs are strongly
resistant toM. tuberculosis infection. Furthermore, simultane-
ous inhibition of the differentiation of Th2 cells and Tregs by
the therapeutic compounds suplatast tosylate ([3-[[4-(3-ethoxy-
2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-
sulfonium 4-methylbenzenesulfonate) and D4476 (4-[4-(2,3-
dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidiazol-2-yl]
benzene), respectively, substantially reduced bacterial growth in
differentorgans.Therefore,our findingshave important implications
for the development of improved tuberculosis therapies.
EXPERIMENTAL PROCEDURES
Ethics Statement—Animal experiments were performed
according to the guidelines approved by the Institutional Ani-
mal Ethics Committee of International Centre for Genetic
Engineering and Biotechnology (ICGEB) (New Delhi, India)
and the Department of Biotechnology guidelines (government
of India). All mice used for experiments were ethically sacri-
ficed by asphyxiation in carbon dioxide according to institu-
tional and Department of Biotechnology regulations.
Bacterial Infections—M. tuberculosis H37Rv strain was
grown in Middlebrook 7H9 broth (BD Biosciences, Sparks,
MD) containing 0.02%Tween 80 tomid-log phase at 37 °C for 3
weeks, aliquoted, and frozen at80 °C until use. Viable bacte-
rial number was determined on 7H11 agar plates (BD Biosci-
ences) with oleic acid albumin dextrose catalase enrichment
(BD Biosciences). Mice were infected via the aerosol route
using the nebulizer compartment of an airborne infection
apparatus. After 30 min of exposure, the deposition of bacteria
was 110 bacteria/lung, which was determined by plating the
lung homogenates after 24 h of infection. The numbers of viable
bacteria in the lung, spleen, and liverofdifferent typesofmicewere
followed at regular time intervals byplating serial dilutions of indi-
vidual organ homogenates onto nutrientMiddlebrook 7H11 agar
plates and counting bacterial colony formation after 21 days of
incubation at 37 °C. All experiments with M. tuberculosis were
performed in a biosafety level III facility approved by our Institu-
tional Biosafety Committee of ICGEB (NewDelhi, India).
Mice—Initially, wild type BALB/c, Stat-6/, T-bet/, and
CD4-TGFRIIDNmicewere obtained fromThe Jackson Labora-
tory, and these strains were subsequently bred in the central
animal facility of ICGEB (NewDelhi, India). Stat-6/, T-bet/,
and CD4-TGFRIIDN mice were intercrossed to obtain Stat-
6/T-bet/, Stat-6/CD4-TGFRIIDN, T-bet/CD4-
TGFRIIDN, or Stat-6/T-bet/CD4-TGFRIIDN mouse
strains. All animals in this study were 6- to 8-week-old females,
BALB/c background, and all experiments were carried out as per
the approved protocol obtained from the Institutional Animal
Ethics Committee.
Drug Treatment—Mice were infected with M. tuberculosis
strain H37Rv as described previously. From day 1 after infec-
tion, animals were treated intraperitoneally with D4476 and/or
suplatast tosylate (purchased from Tocris Biosciences) at 32
nmol/g up to day 44 after infection.
ELISpot Assay—We isolated lung T cells by treatment with
collagenaseA (1mg/ml) andDNase concentration (25l/ml) at
37 °C for 30 min. The content of the lungs was then crushed
through cell strainers with the help of a syringe plunger. Debris
was removed by passing through loosely packed nylon wool
columns. Cells were washed, and CD4 T cells were enriched
with magnetic beads (Miltenyi Biotech). Spleen cells from syn-
geneic uninfected wild type mice were stimulated with com-
plete soluble antigen (CSA; 50 g/ml) of H37Rv for 1 h, -irra-
diated (15 Gy), and considered as antigen-presenting cells
(APCs). CD4 T cells were cultured in the presence of APCs at
a 3:1 ratio for 48 h. Similarly, CD4Tcells obtained from spleen
were cultured in the presence of -irradiated syngeneic APCs
and stimulated with CSA (50 g/ml) as described above. Anti-
gen-specific IFN--, IL-4-, and IL-17-producing cells in
infected lungs and spleen were detected by ELISpot assay (R &
D Systems). After 48 h, CD4 T cells co-cultured with -irra-
diated APCs were seeded in antibody-coated plates at an initial
density of 5  104 cells for lung or 5  105 cells for spleen per
well. After 18 h, plates were developed, and the frequency and
total number of responding cellswere determined.Neither cells
cultured in the absence of CSA nor cells from uninfected mice
produced detectable spots.
Cell Staining and Flow Cytometry—CD4 T cells obtained
from lung and spleen were cultured in the presence of -irradi-
ated syngeneic APCs and stimulated with CSA (50 g/ml) as
described above. The cells (1 104) were surface-stained with
anti-CD4 (clone GK1.5) PerCP, anti-CD25 (clone PC61.5)
APC, and anti-FoxP3 (clone MF23) PE (BD Pharmingen) anti-
bodies. Samples were fixed in a 2% paraformaldehyde solution
in PBS and analyzed using a FACSCanto flow cytometer (BD
Biosciences) and FlowJo software (Tree Star, Inc.).
For mice treated with suplatast tosylate and D4476 intracel-
lular cytokine staining of splenocytes was performed by activat-
ing cells with 50 ng/ml phorbolmyristate acetate and 500 ng/ml
ionomycin in the presence of 10 g/ml brefeldin A (Sigma-
Aldrich or eBiosciences) added during the last 6 h of culture.
Cells were washed twice with PBS and resuspended in a per-
meabilization buffer (Cytofix/Cytoperm kit; BD Biosciences)
and stained with different combinations of the following fluo-
rescently conjugated monoclonal antibodies: anti-mouse CD4
(clone GK1.5) APC (eBioscience), anti-mouse CD4 (clone
GK1.5) PE-Cy5 (eBioscience), anti-mouse CD4 (clone GK1.5)
PE (eBioscience), anti-mouse CD4 (clone GK1.5) FITC
(eBioscience), anti-mouse IFN- (clone XMG1.2) APC (Bioleg-
end), anti-mouse IL-4 (clone 11B11) PE (Biolegend), and anti-
mouse IL-17A (clone TC11-18H10.1) PE (Biolegend). Fluores-
cence intensity was measured by flow cytometry (FACSCalibur
or FACSCantoII; BDBiosciences), and datawere analyzedwith
FlowJo (TreeStar).
Cytokine Assay—Cytokines in the serum and culture super-
natant were assayed by a Luminex microbead-based multi-
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plexed assay using commercially available kits according to the
manufacturer’s instructions (BioPlex, Bio-Rad).
Histology—Lungs from mice at 60 days after infection were
perfused, removed, and fixed in 4.5% formalin, sectioned, and
stained with hematoxylin and eosin.
Bacterial Growth Inhibition Assay—M. tuberculosis strain
H37Rv was grown in 10 ml of Middlebrook 7H9 broth (Becton
Dickinson, Sparks, MD) supplemented with 10% ADC
(BBLTM, BD Biosciences), 0.05% Tween 80, and 0.2% glycerol
at 37 °C under constant shaking. Optical density of the culture
was measured at 600 nm using a spectrophotometer (Perkin-
Elmer Life Sciences), and equal numbers of cells from the cul-
ture were freshly inoculated in a 30-ml flask containing fresh
7H9 broth such that the initial O.D. of the culture was 0.05.
Suplatast tosylate and/or D4476 were added at a dose of 4 nM.
Cells were allowed to grow at 37 °C with constant shaking.
Optical density of each culture was measured and recorded
every 24 h.
Statistical Analysis—Data represent mean  S.D. values of
fourmice per group per time point for experiments with genet-
ically engineered mice and of six mice per group per time point
for experiments with small molecule-mediated immunother-
apy. Statistical analyses were conducted using SPSS10 software.
Significant differences between the groups were determined by
analysis of variance followed by Tukey’s multiple comparison
tests (SPSS Software). A value of p  0.05 was accepted as an
indication of statistical significance. All experiments were
repeated twice.
RESULTS
Development of a Mouse Strain Highly Resistant to M. tuber-
culosis Infection—It has been well established that the Th
cell type elicited determines susceptibility or resistance to
M. tuberculosis infection (5). Thus, to understand the T cell
subsets that are required for host resistance or disease progres-
sion, we have generated animals that are defective in generating
various combinations of Th cell subsets (Table 1). T-bet is a
transcription factor required for Th1 cell differentiation (21),
whereas Stat-6 is a transcription factor required for Th2 cell
differentiation (22), and TGF- is required for the differentia-
tion of Tregs (23). Therefore, we crossed mouse strains defi-
cient in these transcription factors or with a CD4 T cell lin-
eage-specific TGF--signaling deficiency to generate T-bet/
CD4-TGFRIIDN, Stat-6/ CD4-TGFRIIDN, and T-bet/
Stat-6/ CD4-TGFRIIDN mice, which are unable to mount
Th1 cells andTregs, Th2 cells andTregs, or Th1 cells, Th2 cells,
and Tregs, respectively (Table 1). As indicated in Table 1, mice
that are deficient in Stat-6 and express a dominant-negative
form of the TGF- receptor in the CD4 T cell lineage (i.e.
Stat-6/CD4-TGFRIIDN mice) are defective in the genera-
tion of Th2 cells (22) and Tregs (24, 25). We found that Stat-
6/CD4-TGFRIIDN mice exhibited high resistance to
M. tuberculosis infection as determined from the cfu counts in
lung, spleen, and liver following infection with virulent
M. tuberculosis (Fig. 1A). We were unable to identify any
necrotic granulomas in these animals (Fig. 1B). Stat-6/ and
CD4-TGFRIIDN animals individually showed partial resis-
tance to infection (Fig. 2, A and E). Interestingly, any of these
strains that were also deficient in T-bet, a transcription factor
that is critical for Th1 cell differentiation (26), were susceptible
toM. tuberculosis infection, as shown by bacterial counts (Figs.
1, A, and 2, A and E) and the presence of necrotic granulomas
(Figs. 1B, and 2, B and F).
Dynamics of T Cell Subsets Induced byM. tuberculosis in Dis-
tinct Genetically Engineered Mice—To provide insight into the
Th cell responses induced byM. tuberculosis in distinct genet-
ically engineered animals, we isolated CD4 T cells from the
lungs and spleens and determined the frequency of cells with a
Th1,Th2,Th17, andTreg cell phenotype.Asexpected, Stat-6/
CD4-TGFRIIDN mice induced large numbers of IFN--pro-
ducing cells, whereas numbers of IL-4-, IL-17-, and FoxP3-pos-
itive cells were negligible (Fig. 1, C and D). Cytokines in serum
and in M. tuberculosis antigen-stimulated splenocyte cultures
similarly revealed that Stat-6/CD4-TGFRIIDN mice pro-
duced high levels of IFN- but were unable to generate IL-4,
IL-17, TGF-, and IL-10 T cell responses (supplemental Table
1). Interestingly, we observed that all groups of animals on the
CD4-TGFRIIDNbackground exhibited a dramatic increase in
IFN--producing cells in both lung and spleen (Fig. 1, C andD,
and Fig. 2, G and H). Consistent with this finding, we detected
large amounts of IFN- in the serum and in the supernatant of
M. tuberculosis-derived CSA-challenged splenocyte cultures
from animals that were on a CD4-TGFRIIDN and/or Stat-
6/ background (supplemental Table 1), whereas mice that
were on a T-bet-deficient background showed modestly
enhanced numbers of IL-4- and/or FoxP3-positive cells (Fig. 1,
G and H). In sharp contrast, animals that were on a T-bet/
background exhibited high levels of IL-4-, TGF--, IL-10-, and
FoxP3-positive cells as well as high levels of IL-4, TGF-, and
IL-10 in serum and in response to CSA stimulation (Fig. 1,C,D,
G, andH, and Fig. 2,C,D,G, andH, and supplemental Table 1).
These observations suggested that, in the absence of Th2 cells
and Tregs, animals generate sufficient immune responses
against M. tuberculosis to resist disease development. On the
other hand, T-bet/Stat-6/CD4-TGFRIIDN mice are
highly susceptible to M. tuberculosis infection (Fig. 1A), sug-
gesting that the observed resistance of Stat-6/ CD4-
TGFRIIDN mice to M. tuberculosis infection is conferred by
potent Th1 responses.
SmallMolecule-mediated Immunotherapy ofM. tuberculosis
Infection—The preceding sections revealed that simultaneous
inhibition of Th2 cells and Tregs might have therapeutic bene-
fits for treatment of tuberculosis. IL-4 and TGF- play critical
TABLE 1
Genetically engineered mice used in this study and T helper cell sub-
sets produced by them
Mouse strain
Subsets of T helper cells
Th1 Th2 Th17 Treg
WT    
Stat6/    
Tbet/    
CD4-TGFRIIDN    
Stat6/Tbet/    
Stat6/CD4-TGFRIIDN    
Tbet/CD4-TGFRIIDN    
Stat6/Tbet/CD4-TGFRIIDN    
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roles in the differentiation of Th2 cells and Tregs, respectively.
Therefore, we tested whether combined inhibition of IL-4 and
TGF- signaling with small molecules could confer resistance
to M. tuberculosis infection. Suplatast tosylate disrupts IL-4
signaling and thus inhibits activation and differentiation of Th2
cells (27). Similarly, D4476 inhibits TGF- signaling (28). We
infected wild type BALB/c animals with a low dose ofM. tuber-
culosis H37Rv through the aerosol route and then treated the
animals with these two drugs. As expected, combined treat-
ment highly diminished bacterial burden in lung, spleen, and
liver (Fig. 3, A and B). Necrotic granulomas were also markedly
reduced in animals that received combined therapy, although
lungs were modestly inflamed (Fig. 3C). Either of these com-
pounds alone was only partially effective. However, combined
therapy dramatically enhanced induction of IFN--producing
cells and inhibited induction of IL-4-as well as FoxP3-produc-
ing cells but had modest effects on IL-17-producing cells (Fig.
4). Interestingly, combined treatment was unable to protect
T-bet/ mice against M. tuberculosis infection, suggesting
that the therapeutic effects of the small molecules were medi-
ated by promoting protective Th1 cell responses (data not
shown).
FIGURE 1. Stat-6/CD4-TGFRIIDN animals are resistant to M. tuberculosis infection. A, wild type BALB/c, STAT-6/CD4-TGFRIIDN, and STAT-
6/T-bet/CD4-TGFRIIDNmicewere infectedwith lowdose (110 cfu)H37Rv through the aerosol route. Bacterial burdensweredetermined in theorgans
and at the time points indicated. Data represent mean  S.D. values of four mice per group per time point, and the experiment was repeated twice. B,
histological photomicrographs (40) of lung sections (6m)ofwild type BALB/c, STAT-6/CD4-TGFRIIDN, and STAT-6/T-bet/CD4-TGFRIIDNmice at
60 days after infection, stained with hematoxylin and eosin. C, ELISPOT assay to show the cytokine expression in CD4 T cells in lung and spleen of M. tuber-
culosis-infected wild type BALB/c, STAT-6/CD4-TGFRIIDN, and STAT-6/T-bet/CD4-TGFRIIDN mice. D, prevalence of CD4CD25FoxP3 T cells in
BALB/c, STAT-6/CD4-TGFRIIDN, and STAT-6/T-bet/CD4-TGFRIIDN mice was determined by FACS analysis. E, wild type BALB/c and T-bet/mice
were infected with low dose (110 cfu) H37Rv through the aerosol route. Bacterial burdens were determined in the organs and at the time points indicated.
Data representmean S.D. values of fourmice per groupper time point, and the experimentwas repeated twice. F, photomicrographs (40) of lung sections
(6 m) of T-bet/ mice at 60 days after infection, stained with hematoxylin and eosin. G, cytokine expression in CD4 T cells of lung and spleen from
M. tuberculosis infected wild type BALB/c and T-bet/mice was determined by ELISPOT assay. H, prevalence of CD4CD25FoxP3 T cells in pooled T cells
obtained from lung and spleen of infected wild type BALB/c and T-bet/mice. Significant differences between the groups were determined by analysis of
variance followed by Tukey’s multiple comparison tests. Asterisk indicates statistical significance, p 0.05.
Immunotherapy of Tuberculosis
JUNE 6, 2014•VOLUME 289•NUMBER 23 JOURNAL OF BIOLOGICAL CHEMISTRY 16511
 by guest on February 16, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The studies described in the preceding sections suggested
that simultaneous inhibition of IL-4 and TGF- signaling per-
mits the development of enhanced Th1 responses and facili-
tates clearance of M. tuberculosis. Next, we tested whether
these compounds have any direct effects on the growth of the
M. tuberculosis organisms. As expected, the compounds did
not show any significant effect on bacterial growth in liquid
culture (supplemental Fig. 1).
TGF- is an important regulatory cytokine that plays a critical
role in the maintenance of immune tolerance (28). TGF--defi-
cient animals areembryonically lethal, andCD4-TGFRIIDNani-
malsdisplay inflammation inmultipleorganswithenhancedauto-
activation of Th1 and Th2 cells (29, 30). Therefore, prolonged
inhibition of TGF- might unmask autoimmunity, which would
limit its therapeutic use. However, we did not observe any
enhanced inflammation upon infection of CD4-TGFRIIDN ani-
mals with M. tuberculosis. Likewise, the short treatment period
employed with suplatast tosylate and D4476 did not culminate
into signs of excessive inflammation (data not shown).
DISCUSSION
It is now well accepted that Th cells play a central role in
determining susceptibility or resistance to M. tuberculosis
infection (31). During progression of tuberculosis,M. tubercu-
losis elicits Th2 and Treg cell responses in susceptible hosts,
which facilitates disease progression by antagonizing host pro-
tective immune responses. Our results suggested that Th1 cells
are necessary and sufficient for resistance against tuberculo-
FIGURE 2. Stat-6/ and CD4-TGFRIIDN animals are partially resistant to M. tuberculosis infection. A, wild type BALB/c, STAT-6/, and STAT-
6/T-bet/micewere infectedwith lowdose (110 cfu) H37Rv through the aerosol route. Bacterial burdenswere determined in the organs and at the time
points indicated. Data represent mean S.D. values of four mice per group per time point, and the experiment was repeated twice. B, histological photomi-
crographs (40) of lung sections (6m) of STAT-6/ and STAT-6/T-bet/mice at 60 days after infection. C, ELISPOT assay of cytokine expression in CD4
T cells of lungand spleen fromM. tuberculosis-infectedwild typeBALB/c, STAT-6/, andSTAT-6/T-bet/mice.D, prevalenceof CD4CD25FoxP3T cells
was determined by FACS analysis. E, wild type BALB/c, CD4-TGFRIIDN, and T-bet/CD4-TGFRIIDN mice were infected with low dose (110 cfu) H37Rv
through the aerosol route. Bacterial burdens were determined in the organs and at the time points indicated. Data represent mean S.D. values of four mice
per group per time point, and the experiment was repeated twice. F, Histological photomicrographs (40) of lung sections (6 m) of CD4-TGFRIIDN, and
T-bet/CD4-TGFRIIDN mice at 60 days after infection. G, ELISPOT assay of cytokine expression in CD4 T cells of lung and spleen from M. tuberculosis-
infected wild type BALB/c, CD4-TGFRIIDN, and T-bet/CD4-TGFRIIDN mice. H, prevalence of CD4CD25FoxP3 T cells in BALB/c, CD4-TGFRIIDN, and
T-bet/CD4-TGFRIIDN mice was determined by FACS analysis.
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sis, which is in agreement with recently published reports
(32). At any given time Th1 and Th2 cells are in a dynamic
balance and, thus, mounting Th2 cells decreases host pro-
tective Th1 responses. In fact, it has been shown that animals
that are unable to mount Th2 responses are partially resis-
tant to M. tuberculosis infection (33). Thus, inhibition of
Th1 responses by down-regulating IL-12 production in
infected cells and eliciting Th2 responses represents a host
immune evasion mechanism employed by M. tuberculosis.
Recently, it has been shown thatM. tuberculosis facilitates not
only Th2 responses but also induces strong Treg cell responses
(34). Treg cells have been implicated in inhibiting host protec-
tive immune responses (34). TGF- is required for the differ-
entiation of Treg cells and is produced by the infected cells and
by mesenchymal stem cells that infiltrate the site of infection
(35, 36). Our data are also consistent with a recent publication
(17) providing evidence for profound expansion of Treg cells in
the draining lymph nodes duringM. tuberculosis infection and
with previous reports that TGF- is required for the expansion
and maintenance of Tregs. In fact, previous data indicated that
mice impaired in TGF- signaling are partially resistant to
M. tuberculosis infection (37).
It has been shown that inhibition of Th2 cells or Tregs indi-
vidually confers partial resistance to M. tuberculosis infection
FIGURE 3. Simultaneous inhibition of Th2 cytokines and TGF- protects against M. tuberculosis infection. Wild type BALB/c and mutant mice were
infected (110 cfu/mice) through the aerosol route with M. tuberculosis (H37Rv). These mice were injected intraperitoneally with D4476 (a TGFRI inhibitor)
and/or suplatast tosylate (a Th2 inhibitor) at 32 nmol/g of body weight starting from the 1st day until the 44th day after aerosol challenge. At different time
points (15, 30, 45 days), six mice from each group were sacrificed, and bacterial loads (cfu) were determined in lungs (A), spleen, and liver (B). C, histological
photomicrographs (10) of lung sections (6 m) at 60 days after infection of the indicated mice, stained with hematoxylin and eosin. Arrows indicate
granulomatic regions. Significant differences between the groups were determined by analysis of variance followed by Tukey’s multiple comparison tests.
Asterisk indicates statistical significance, p 0.05.
FIGURE 4. Intracellular cytokine profiling after combined therapy. FACS data show the number of IFN--, IL-4-, IL-17, as well as FoxP3-producing cells after
combined treatment with suplatast tosylate and D4476.
Immunotherapy of Tuberculosis
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(14, 37, 38). Therefore, to test whether combined inhibition of
these two subsets has additive therapeutic effects, we generated
animals that are defective in both of these subsets (Stat-6/
CD4-TGFRIIDN mice). These animals exhibited increased
resistance toM. tuberculosis infection compared with the indi-
vidual strains. Therefore, these data suggest that simultaneous
inhibition of Th2 cells and Tregs has a superior therapeutic
benefit compared with inhibition of the individual subsets
alone. Nevertheless, we cannot formally exclude the possibility
that deficiency in Stat-6 and TGF- additionally influences
M. tuberculosis infection in a manner that is independent of
their effects on Th2 and Treg cell responses, respectively.
Inhibiting the differentiation of Th2 cells and Tregs can be
achieved by antibodies against IL-4 and TGF-. However, anti-
bodies are expensive and have several disadvantages such as
antigenicity. Therefore, we investigated therapeutic small mol-
ecules that could inhibit Th2 cells and Tregs. Suplatast tosylate
has been shown to disrupt production of IL-4 and other Th2-
type cytokines without impeding IFN- production (39).While
its molecular mechanism of action has not been fully eluci-
dated, suplatast tosylate inhibits IL-4 production by its direct
effects on T cells (40). D4476 is an ALK5 inhibitor and thus
prevents Smad3 activation and suppresses TGF- receptor I
gene expression (28). Simultaneous treatment ofM. tuberculo-
sis infectedmicewith these two compounds dramatically inhib-
ited bacterial burden in different organs. This mode of therapy
was not effective inT-bet-deficient animals, suggesting that it is
mainly dependent on the induction of Th1 cell responses.How-
ever, it remains possible that these reagents have effects on
M. tuberculosis infection that are independent of their effects
on Th2 and Treg cell responses. Nevertheless, our findings
demonstrate that small molecule-directed immunotherapy is
effective for the treatment of tuberculosis.
The therapeutic agents employed here are not directed
against the harbored pathogen itself. Thus, this mode of
therapy should not discriminate between different types of
M. tuberculosis pathogens, regardless of their antibiotic resis-
tance properties.
Although our therapeutic strategy is novel, we believe that it
cannot be employed for a prolonged time period. TGF- plays
an important role in maintaining immune homeostasis and
transgenic animals expressing a dominant negative form of
TGF-RII exhibit multi organ inflammation and death (29, 30).
Similarly, inhibition of Th2 cells may lead to susceptibility
toward parasitic infections (41). Thus, we propose that these
compounds could be employed in human patients for relatively
short treatment periods. Combining these immunomodulators
with antibiotics might reduce the length of treatment and thus
avoid the generation of multiple drug-resistant and extremely
drug-resistant strains.
In summary, our results have revealed that simultaneous
inhibition of Th2 cells and Tregs has great potential for treat-
ment of tuberculosiswith smallmolecules. As these therapeutic
agents are not directed toward the harbored pathogens, they
should avoid the generation of multiple drug-resistant and
extremely drug-resistant variants. In addition, these therapeu-
tic agents are less expensive than conventional recombinant
therapeutic agents such as antibodies and should avoid compli-
cations associated with recombinant immunotherapeutic
agents.
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